<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-12-05</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-12-05</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>74</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç©ºé—´è½¬å½•ç»„å­¦æŠ€æœ¯é¦–æ¬¡æ­ç¤ºäº†èƒ°è…ºç™Œè‚¿ç˜¤ç»†èƒèº«ä»½å¯¹å¾®ç¯å¢ƒçš„å†³å®šæ€§å½±å“ï¼Œå¹¶å‘ç°IFITM3-METç›¸äº’ä½œç”¨é©±åŠ¨EGFRçªå˜NSCLCè€è¯æ–°æœºåˆ¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å¾®ç¯å¢ƒä¸è€è¯æœºåˆ¶ï¼šè§£æEGFRçªå˜NSCLCã€èƒ°è…ºç™Œã€æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰ç­‰å¤šç§ç™Œç—‡ä¸­ï¼Œè‚¿ç˜¤ç»†èƒã€å…ç–«ç»†èƒåŠåŸºè´¨ç»†èƒé—´çš„ç©ºé—´äº’ä½œå¦‚ä½•å½±å“æ²»ç–—ååº”ã€‚<br />
- ç–¾ç—…åˆ†å­æœºåˆ¶ï¼šæ¢ç´¢çš®è‚¤ç—…ç—¤ç–®ã€ç¥ç»ç³»ç»Ÿç–¾ç—…å¸•é‡‘æ£®ç—…ã€å®«é¢ˆå†…è†œç™Œæ¶å˜ç­‰ç–¾ç—…çš„ç»†èƒåŠåˆ†å­æœºåˆ¶ã€‚<br />
- è‚¿ç˜¤å…ç–«ä¸æ²»ç–—ï¼šç ”ç©¶è‚¿ç˜¤å¾®ç¯å¢ƒä¸­çš„å…ç–«ç»†èƒè°ƒæ§ï¼ˆå¦‚å·¨å™¬ç»†èƒã€ILC2ï¼‰ã€ç©ºé—´åˆ†é¦å¯¹æ”¾ç–—ç–—æ•ˆçš„å½±å“ã€ä»¥åŠå¾®ç”Ÿç‰©ç»„ä¸è„‘è‚¿ç˜¤çš„å…³è”ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- å¤šæ¨¡æ€ç©ºé—´ç»„å­¦ï¼šç»“åˆç©ºé—´è½¬å½•ç»„å­¦ã€Nanostring CosMxã€ChIP-seqã€ATAC-seqç­‰æŠ€æœ¯ï¼Œå®ç°å¯¹è‚¿ç˜¤å¾®ç¯å¢ƒå’ŒåŸºå› è°ƒæ§ç½‘ç»œçš„ç²¾ç»†è§£æã€‚<br />
- å•ç»†èƒè½¬å½•ç»„å­¦ï¼šåº”ç”¨äºå¸•é‡‘æ£®ç—…ç±»å™¨å®˜æ¨¡å‹ï¼Œæ­ç¤ºå…¶åˆ†å­è„†å¼±æ€§ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ–°å…´è¯æ®è¡¨æ˜ï¼Œè‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒï¼ˆTAMï¼‰åœ¨æŠ—ä½“ä¾èµ–æ€§ç»†èƒåå™¬ä½œç”¨ï¼ˆADCPï¼‰ä¸­èµ·æ ¸å¿ƒä½œç”¨ï¼Œä¸ºç™Œç—‡å…ç–«æ²»ç–—æä¾›äº†æ–°è§†è§’ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
-   å¼€å‘é¶å‘åˆ†æ³Œè›‹ç™½ SCUBE3 çš„ç–—æ³•ï¼Œä»¥æŠ‘åˆ¶è‡´ç™Œä¿¡å·ä¼ å¯¼å¹¶è¯±å¯¼æŠ—è‚¿ç˜¤å…ç–«ã€‚<br />
-   ç ”ç©¶é“å‡‹äº¡ï¼ˆFerroptosisï¼‰ä½œä¸ºä¸€ç§æ–°å‹ç¨‹åºæ€§ç»†èƒæ­»äº¡ï¼Œä»¥æ€æ­»è‚¿ç˜¤ç»†èƒã€æŠ‘åˆ¶è½¬ç§»å¹¶é€†è½¬æ²»ç–—è€è¯æ€§ã€‚<br />
-   æ¢ç´¢å—æŸçº¿ç²’ä½“è½¬ç§»è‡³ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFï¼‰å¦‚ä½•ä¿ƒè¿›EGFRçªå˜è‚ºç™Œçš„TKIè€è¯æ€§ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
-   åˆ©ç”¨æŠ—ä½“ç‰‡æ®µï¼ˆå¦‚ GPC3 é¶å‘çš„[68Ga]Ga-XH-06ï¼‰è¿›è¡ŒPETå½±åƒï¼Œä»¥æé«˜è‚ç»†èƒç™Œï¼ˆHCCï¼‰çš„è¯Šæ–­ç²¾åº¦ã€‚<br />
-   é€šè¿‡å¤šç»„å­¦åˆ†æï¼ˆé—ä¼ ã€è¡¨è§‚é—ä¼ ã€è½¬å½•ã€è›‹ç™½è´¨ç»„ï¼‰æ·±å…¥è§£æå°ç»†èƒè‚ºç™Œï¼ˆSCLCï¼‰çš„å¼‚è´¨æ€§ã€å¾®ç¯å¢ƒç‰¹å¾åŠç”Ÿç‰©æ ‡å¿—ç‰©æ™¯è§‚ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (63æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE288758 EGFRçªå˜å‹éå°ç»†èƒè‚ºç™Œä¸­ä¸é¶å‘æ²»ç–—è€è¯æ€§ç›¸å…³çš„è‚¿ç˜¤å¾®ç¯å¢ƒç©ºé—´åŠ¨æ€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€tumor microenvironmentã€resistanceã€spatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Satoshi Nakamaura ; Daisuke Shibahara ; Kentaro Tanaka ; Yasuyuki Kishikawa ; Mikiko Hashisako ; Keita Nakatomi ; Noriaki Nakagaki ; Mikihiro Kohno ; Koichi Azuma ; Ritsu Ibusuki ; Kohei Otsubo ; Yasuto Yoneshima ; Eiji Iwama ; Yoshinao Oda ; Isamu OkamotoSeries Type : OtherOrganism : Homo sapiensEpidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide therapeutic benefit in EGFR mutationâ€“positive nonâ€“small cell lung cancer, but some individuals develop early resistance. We performed spatial transcriptomics analysis of pre- and posttreatment tumor samples from the same patients to explore the underlying mechanisms of such early resistance. The proportion and activation of fibroblasts increased in association with the development of early resistance, whereas a distinct tumor cell cluster showed activation of tumor necrosis factorâ€“Î± signaling via the NF-ï«B pathway even before treatment. Also in the early resistance sample, specific tumor cell clusters interacted with immune and stromal cells. Immature tertiary lymphoid structures (TLSs) were enriched in the early resistance sample, whereas mature TLSs were observed in the long-term response sample. These findings implicate tumor heterogeneity and an inflammatory tumor microenvironment in early EGFR-TKI resistance, providing insight into potential therapeutic strategies to improve treatment outcomes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288758" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE282302 èƒ°è…ºç™ŒåŸä½å¤šæ¨¡æ€è¡¨å¾æ­ç¤ºè‚¿ç˜¤ç»†èƒç‰¹æ€§æ˜¯å‘¨å›´å¾®ç¯å¢ƒçš„å†³å®šæ€§å› ç´  [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Anna Lyubetskaya ; Brian Rabe ; Andrew J Kavran ; Yulong Bai ; Andrew Fisher ; Hannah Pliner ; Alba Font-Tello ; Anne Lewin ; Ruifeng Hu ; Alexandre P Alloy ; Yelena Cheng ; Chao Dai ; Yunfan Fan ; Constance Brett ; Todd Brett ; Lauren Giampapa ; SÃ¶ren R Stahlschmidt ; Fayaz Seifuddin ; Steven Vasquez Grinnell ; Daniel Carrera ; Carlos Rios ; Tom Lila ; Pradeep Kar ; Abhishek Shukla ; Rachael Bashford-Rogers ; Lara Heij ; Mike Mason ; Ryan Golhar ; Isaac Neuhaus ; Enas A Shah ; Jimena T Tinoco ; Benjamin J Chen ; Shivan Sivakumar ; Konstantinos J Mavrakis ; Eugene DrokhlyanskySeries Type : OtherOrganism : Homo sapiensPancreatic Ductal Adenocarcinoma (PDAC) is heterogeneous with low tumor purity, prominent microenvironment and complex architecture, which preclude identification of shared tumor intrinsic biology within and across patients. We overcame these challenges by applying spatial omics approaches â€“ providing necessary resolution and context â€“ to primary untreated PDAC tumors from 39 patients capturing 340K low-bulk and 530K single-cell spatial transcriptomes. We observe a spectrum of classical-to-basal tumor subtypes present within all patients. We identify a distinct population of proliferative tumor cells enriched for the DNA synthesis-condensation-mitosis transcriptional network suggesting this subset disproportionately contribute to tumor growth. Furthermore, we characterize the microenvironment surrounding each tumor subtype and observe that basal identity is contextually defined by collagen, hypoxic adaptation and fibroblast neighbors expressing activated stroma and interferon stimulated gene therapy resistance signatures. Lastly, leveraging orthogonal patient, cell and mouse data, we determine which aspects of PDAC biology are recapitulated in bulk datasets and reductionist models.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282302" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE311909 ä¸€ä¸ªå¯é¶å‘çš„å‘è‚²ç¨‹åºå…±åŒè°ƒæ§è¡€ç®¡ç”Ÿæˆå’Œå…ç–«é€ƒé€¸ [ç©ºé—´è½¬å½•ç»„å­¦]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Markus Schober ; Iman Osman ; Robert Stagnitta ; Pietro Berico ; Eva HernandoSeries Type : OtherOrganism : Homo sapiensUltraviolet (UV)-induced DNA mutations produce genetic drivers of cutaneous melanoma initiation and numerous neoantigens that can trigger anti-tumor immune responses in the host. Consequently, melanoma cells must rapidly evolve to evade immune detection by simultaneously modulating cell-autonomous epigenetic mechanisms and tumor-microenvironment interactions. Angiogenesis has been implicated in this process; although an increase of vasculature facilitates the immune response in normal tissue, solid tumors manage to somehow enhance blood flow while preventing immune cell infiltration. By comparing the expression of transcription factors (TFs) across early-stage melanoma, naevi, and other cancer types, we found the homeodomain-containing TF HOXD13 drives a melanoblast-like developmental program, which is upregulated in melanoma and strongly correlated with angiogenesis and immune cell exclusion. Using transcriptomics, 3D chromatin profiling, and in vivo models, we demonstrate that HOXD13 upregulation promotes tumor growth in vivo by concomitantly enhancing angiogenesis and suppressing T-cell infiltration. HOXD13 orchestrates 3D chromatin contacts between distal enhancers and promoters, simultaneously activating VEGFA, SEMA3A, and CD73. VEGFA and SEMA3A remodel the tumor vasculature and CD73 elevates extracellular levels of adenosine, a vasodilator and immune suppressor that binds adenosine receptors (AdR) on endothelial and T cells. In line with these findings, HOXD13-induced growth advantage in vivo was significantly reversed by the concomitant administration of VEGFR and AdR inhibitors. By revealing a dual pro-angiogenic and immunosuppressive HOXD13-CD73/VEGF gene regulatory axis, we identify a subset of patients who might benefit from combinations of AdR and VEGFR inhibitors which are currently being tested in clinical trials.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311909" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE301973 å¥¥å¸Œæ›¿å°¼æ²»ç–—å‰EGFRçªå˜å‹éå°ç»†èƒè‚ºç™Œçš„ç©ºé—´è½¬å½•ç»„å­¦</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ritsu Ibusuki ; Eiji Iwama ; Atsushi Shimauchi ; Hiromu Kawano ; Satoshi Nakamura ; Yui MiyazakiSeries Type : OtherOrganism : Homo sapiensEGFR-mutant non-small cell lung cancer (NSCLC) is commonly treated with EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib. However, the development of resistance remains a major clinical challenge, with various resistance mechanisms having been identified. Emerging evidence suggests that the tumor microenvironment (TME) may contribute to this resistance. In this study, we analyzed the TME of pre-treatment tumor samples from EGFR-mutant NSCLC patients using the Visium HD spatial transcriptomics platform to explore its potential role in the development of resistance.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301973" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE301280 ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºå¯»å¸¸ç—¤ç–®ä¸­è„‚è´¨ä»£è°¢åŠŸèƒ½éšœç¢å’Œæ¯›å›Šçš®è„‚è…ºåˆ†åŒ–å¼‚å¸¸</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolismã€spatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Joseph S Durgin ; Sunny Y WongSeries Type : OtherOrganism : Homo sapiensAcne vulgaris is a common skin condition involving complex interactions among lipid-secreting sebaceous glands, keratinocytes, immune cells, and microbiota. While retinoids are effective for treating acne, disease pathogenesis remains poorly understood. In particular, it remains unclear how different subtypes of acne, including inflammatory (pustular) and non-inflammatory (comedonal) lesions, vary in gene expression, signaling, and sebaceous gland involvement. Here, we performed spatial transcriptomics on healthy, non-lesional, comedonal, and pustular acne skin using a custom panel targeting sebaceous differentiation, lipid metabolism, and retinoid signaling pathways. We also designed a specialized segmentation pipeline to improve transcript assignment in the spatially complex sebaceous gland. Our analyses identified a PPARG+ transitional basal cell state in sebocytes and revealed that comedonal skin upregulates sebogenesis genes, whereas pustular skin downregulates sebogenesis. Both lesion types exhibit increased AP-1 transcription factors and elevated FABP5, a chaperone that blunts retinoic acid receptor signaling. Finally, we demonstrate that an AP-1 inhibitor, T-5224, strongly downregulates FABP5 in human keratinocytes and reduces pustule formation in a mouse model of high fat diet-induced folliculitis. Altogether, these findings indicate that altered lipogenesis, retinoid signaling, and keratinocyte differentiation are key features of acne, and nominate AP-1 and FABP5 as potential novel therapeutic targets.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301280" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE289619 IFITM3-MET ç›¸äº’ä½œç”¨é€šè¿‡ AKT é€šè·¯æ¿€æ´»é©±åŠ¨ EGFR çªå˜å‹éå°ç»†èƒè‚ºç™Œä¸­çš„å¥¥å¸Œæ›¿å°¼è€è¯ II</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ritsu Ibusuki ; Eiji Iwama ; Atsushi Shimauchi ; Hiromu Kawano ; Shun Mizusaki ; Satoshi Nakamura ; Isamu OkamotoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDespite an initial favorable response of EGFR mutant nonâ€“small cell lung cancer (NSCLC) to osimertinib, an EGFR tyrosine kinase inhibitor (TKI), resistance inevitably develops. We here performed transcriptomics analysis of pretreatment specimens and identified IFITM3 as a gene specifically upregulated in tumors that develop early resistance to osimertinib. Immunohistochemistry confirmed patients with IFITM3-positive tumors experienced a shorter progression-free survival. Spatial transcriptomics and other analyses further revealed that IFITM3 expression was increased in response to cytokines derived from the tumor microenvironment (TME) during osimertinib treatment. IFITM3 was found to promote the development of osimertinib resistance through interaction with MET and activation of the AKT pathway. Furthermore, combined treatment with a MET inhibitor suppressed the development of osimertinib resistance in a mouse model. Our findings thus reveal that upregulation of IFITM3 represents a previously unrecognized mechanism of osimertinib resistance, and they suggest that targeting the IFITM3-MET axis may improve treatment outcomes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289619" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE289383 IFITM3-MET ç›¸äº’ä½œç”¨é€šè¿‡ AKT é€šè·¯æ¿€æ´»é©±åŠ¨ EGFR çªå˜å‹éå°ç»†èƒè‚ºç™Œçš„å¥¥å¸Œæ›¿å°¼è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€resistanceã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ritsu Ibusuki ; Eiji Iwama ; Atsushi Shimauchi ; Hiromu Kawano ; Shun Mizusaki ; Satoshi Nakamura ; Isamu OkamotoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDespite an initial favorable response of EGFR mutant nonâ€“small cell lung cancer (NSCLC) to osimertinib, an EGFR tyrosine kinase inhibitor (TKI), resistance inevitably develops. We here performed transcriptomics analysis of pretreatment specimens and identified IFITM3 as a gene specifically upregulated in tumors that develop early resistance to osimertinib. Immunohistochemistry confirmed patients with IFITM3-positive tumors experienced a shorter progression-free survival. Spatial transcriptomics and other analyses further revealed that IFITM3 expression was increased in response to cytokines derived from the tumor microenvironment (TME) during osimertinib treatment. IFITM3 was found to promote the development of osimertinib resistance through interaction with MET and activation of the AKT pathway. Furthermore, combined treatment with a MET inhibitor suppressed the development of osimertinib resistance in a mouse model. Our findings thus reveal that upregulation of IFITM3 represents a previously unrecognized mechanism of osimertinib resistance, and they suggest that targeting the IFITM3-MET axis may improve treatment outcomes.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289383" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE310388 èƒ°è…ºç™ŒåŸä½å¤šæ¨¡æ€è¡¨å¾æ­ç¤ºè‚¿ç˜¤ç»†èƒç‰¹æ€§æ˜¯å‘¨å›´å¾®ç¯å¢ƒçš„å†³å®šæ€§å› ç´ ã€‚[RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€cancerã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Anna Lyubetskaya ; Brian Rabe ; Andrew Kavran ; Yulong Bai ; Andrew Fisher ; Alba Font-Tello ; Anne Lewin ; Hannah Pliner ; Yunfan Fan ; Lauren Giampapa ; Yelena Cheng ; Chao Dai ; Ruifeng Hu ; Tom Lila ; Alexandre P Alloy ; Mike Mason ; Constance Brett ; Todd Brett ; Fayaz Seifuddin ; Steven Vasquez Grinnell ; Soren R Stahlschmidt ; Yilin Zhao ; Ryan Golhar ; Isaac Neuhaus ; Daniel Carrera ; Carlos Rios ; Pradeep Kar ; Abhishek Shukla ; Rachael Bashford-Rogers ; Matthew J Meyer ; Enas Abu Shah ; Lara Heij ; Shivan Sivakumar ; Jimena Trillo Tinoco ; Benjamin J Chen ; Konstantinos J Mavrakis ; Eugene DrokhlyanskySeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensPancreatic ductal adenocarcinoma is heterogeneous, with low tumor purity, a prominent microenvironment, and complex architecture, which preclude the identification of shared tumor-intrinsic and stromal biology within and across patients. We overcame these challenges by achieving necessary resolution and context through the application of complimentary genomics, pathology and machine learning approaches to characterize primary untreated tumors from 39 patients. We capture 340K spatial low-bulk and 530K spatial single-cell transcriptomes and observe a spectrum of classical-to-basal tumor subtypes present within all patients. We find each subtype has distinct regulators, stromal neighborhoods, microenvironment, extracellular matrix and histology corresponding to multiple immunosuppressive and therapy resistance mechanisms. We define key tumor heterogeneity features including the presence of mixed KRAS mutations and tertiary lymphoid structures; identifying biomarkers that distinguish the latter from lymph nodes. Lastly, leveraging patient, cell and mouse data, we determine which aspects of tumor biology are recapitulated in bulk datasets and reductionist models.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310388" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE280735 PRDM16ä»‹å¯¼çš„ä»£è°¢é‡ç¼–ç¨‹é©±åŠ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…äº§ç”Ÿé˜¿ç³–èƒè‹·è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šleukemiaã€metabolicã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Junji Ikeda ; Hiroyoshi KunimotoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAcute myeloid leukemia (AML) patients with high PRDM16 expression frequently experience induction failure and have a poor prognosis. However, the molecular mechanisms underlying these clinical features are elusive. We found that murine AML cells transformed by MLL::AF9 fusion and oncogenic short-isoform Prdm16 overexpression (hereafter, MF9/sPrdm16) exhibited resistance to cytarabine (AraC), but not to anthracycline, both in vitro and in vivo. Intriguingly, MF9/sPrdm16 cells displayed a gene expression signature of high oxidative phosphorylation (OxPHOS) and increased mitochondrial respiration. The inhibition of mitochondrial respiration with metformin or tigecycline abrogated AraC resistance in MF9/sPrdm16 cells via an energetic shift toward low OxPHOS status. Furthermore, sPrdm16 upregulated c-Myc and the glutamine transporter Slc1a5, activating TCA cycle and glutaminolysis. Of note, both OxPHOS and MYC-target gene signatures were significantly enriched in AML patient samples with high PRDM16 expression. Together, we showed that PRDM16 overexpression activates mitochondrial respiration through metabolic reprogramming via c-MYC-SLC1A5-Glutaminolysis axis, thereby conferring AraC resistance on AML cells. These results suggest that targeting mitochondrial respiration might be a novel treatment strategy to overcome chemoresistance in AML patients with high PRDM16 expression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280735" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE279905 ç©ºé—´åˆ†å‰²å¯¹è‚¿ç˜¤å…ç–«ååº”å½±å“çš„ç»¼åˆè¯„ä»·ï¼šä»¥èƒ¶è´¨æ¯ç»†èƒç˜¤è´¨å­å¾®æŸæ”¾å°„æ²»ç–—ä¸ºä¾‹ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€spatial<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Lorea Iturri ; Miriam Riquelme-Perez ; Pierre-Emannuel BontÃ© ; Sarah Potiron ; Christel Goudot ; Marjorie Juchaux ; Elise Brisebard ; CristÃ¨le Gilbert ; Julie Espenon ; RamÃ³n Ortiz ; Annalisa Patriarca ; Ludovic de Marzi ; SebastiÃ¡n Amigorena ; Yolanda PrezadoSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusTreating radioresistant tumors like glioblastoma multiforme (GBM) remains a challenge exacerbated by their immunosuppressive nature. Radiation therapy has an immunomodulatory (immunosuppressive or immunostimulatory) role. The nature of the effects would depend on the total dose, dose per fraction, dose delivery method and treatment length. It is well-known that conventional fractionation schemes (2 Gy per fraction during several weeks) are mainly immunosuppressive and that hypofractionation tips the balance towards immune stimulation. However, the use of hypofractionation is restricted in bulky tumours, i.e. gliomas, due to the high risk of toxicity. Therefore, finding new strategies leading to more favourable immune responses while reducing normal tissue toxicities could be a game-changer. This is the case of proton minibeam radiation therapy (pMBRT). However, its immunomodulatory effects are not fully understood. To explore this, we conducted an in-depth characterization of the immune response to a curative dose of pMBRT in a preclinical orthotopic rat model of glioblastoma. Our findings revealed a close association between pMBRT and the immune response. pMBRT increased lymphocyte density in tumors more effectively than conventional proton therapy. Single-cell transcriptomics identified several immune cell types and unique transcriptional changes in tumor immune cells post-pMBRT, including increased antibody production, chemotactic cytokine expression, and interferon responses. These results underscore the critical role of adaptive immunity, specifically T cells, in pMBRT's mechanism. The potential of pMBRT to trigger an anti-tumor immune response in a single radiotherapy session with minimal damage to healthy tissue makes it a promising candidate for future clinical trials and radio-immunotherapy combinations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279905" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 53 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (11æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>åˆ©ç”¨å·¨å™¬ç»†èƒä»‹å¯¼çš„æŠ—ä½“ä¾èµ–æ€§ç»†èƒåå™¬ä½œç”¨è¿›è¡Œç™Œç—‡å…ç–«æ²»ç–—çš„äº‹å®ä¸å¸Œæœ›ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å…ç–«ã€å·¨å™¬ç»†èƒã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠä¸­ä½¿ç”¨çš„å•å…‹éš†æŠ—ä½“ï¼ˆmAbsï¼‰å¯é€šè¿‡å…¶ Fc ç»“æ„åŸŸä½œç”¨å…ç–«ç³»ç»Ÿï¼Œè¯±å¯¼è¯¸å¦‚æŠ—ä½“ä¾èµ–æ€§ç»†èƒæ¯’æ€§ï¼ˆADCCï¼‰å’ŒæŠ—ä½“ä¾èµ–æ€§ç»†èƒåå™¬ä½œç”¨ï¼ˆADCPï¼‰ç­‰æ•ˆåº”æœºåˆ¶ã€‚è™½ç„¶è‡ªç„¶æ€æ‰‹ï¼ˆNKï¼‰ç»†èƒå†æ¥è¢«è®¤ä¸ºæ˜¯ ADCC çš„ä¸»è¦ä»‹è´¨ï¼Œä½†æ–°å…´è¯æ®è¡¨æ˜è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒï¼ˆTAMï¼‰ï¼Œå°¤å…¶æ˜¯å•æ ¸ç»†èƒè¡ç”Ÿçš„äºšç¾¤ï¼Œåœ¨ ADCP ä¸­èµ·ç€æ ¸å¿ƒä½œç”¨ã€‚è¿™äº›å·¨å™¬ç»†èƒåœ¨è‚¿ç˜¤å¾®ç¯å¢ƒä¸­ä¸°å¯Œï¼Œè¡¨è¾¾é«˜æ°´å¹³çš„æ´»åŒ– Fc ä¼½é©¬å—ä½“ï¼ˆFcÎ³Rsï¼‰ï¼Œå¹¶ä¿æŒå¼ºå¥çš„åå™¬èƒ½åŠ›ã€‚ç„¶è€Œï¼ŒTAMs çš„å¼‚è´¨æ€§ä»¥åŠå¯¹ä¸åŒè‚¿ç˜¤ç±»å‹ FcÎ³R è¡¨è¾¾æ¨¡å¼çš„æœ‰é™äº†è§£é™åˆ¶äº† ADCP çš„æ²»ç–—åˆ©ç”¨ã€‚æœ¬ç»¼è¿°æ‰¹åˆ¤æ€§åœ°è€ƒå¯Ÿäº†å·¨å™¬ç»†èƒä»‹å¯¼çš„ ADCP å¯¹è‚¿ç˜¤é¶å‘å’Œå…ç–«è°ƒæ§å•æŠ—æŠ—ä½“æ´»æ€§çš„è´¡çŒ®ã€‚æˆ‘ä»¬è®¨è®ºäº† FcÎ³R å¤šæ€æ€§ã€åŒå‹å·¥ç¨‹å’ŒæŠ—ä½“æ•ˆåº”å™¨åŠŸèƒ½å¦‚ä½•å½±å“æ²»ç–—æ•ˆæœï¼Œç‰¹åˆ«å…³æ³¨å¸¸ç”¨çš„è‚¿ç˜¤é¶å‘å’Œå…ç–«è°ƒèŠ‚æŠ—ä½“ã€‚è¿˜æ¢è®¨äº†æŠ‘åˆ¶æ€§å—ä½“å¦‚ FcÎ³RIIbã€CD47 å’Œ PD-1 åœ¨è°ƒèŠ‚ ADCP ä¸­çš„ä½œç”¨ã€‚é’ˆå¯¹è‚¿ç˜¤æŠ—åŸçš„å¤šç‰¹å¼‚æ€§æŠ—ä½“ä¸<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996247019537149952/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>æŠ—ä½“ä»‹å¯¼çš„åˆ†æ³Œè›‹ç™½ SCUBE3 é€šè¿‡æŠ‘åˆ¶è‡´ç™Œä¿¡å·ä¼ å¯¼å¹¶è¯±å¯¼æŠ—è‚¿ç˜¤å…ç–«æ¥æŠ‘åˆ¶ç™Œç—‡è¿›å±•</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç™Œç—‡ã€å…ç–«ã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: é’ˆå¯¹åŒæ—¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿å’Œè¿›å±•ã€è¯±å¯¼æ²»ç–—è€è¯æ€§å’ŒæŠ‘åˆ¶æŠ—è‚¿ç˜¤å…ç–«çš„å› ç´ çš„æ–¹æ³•ï¼Œæ˜æ˜¾ä¼˜äºä»…é’ˆå¯¹å…¶ä¸­ä¸€ç§è‚¿ç˜¤ä¿ƒè¿›è¿‡ç¨‹çš„æ²»ç–—ã€‚é€šè¿‡å…¨é¢çš„åŠŸèƒ½ä¸§å¤±åŸºå› ç»„ç­›æŸ¥ï¼Œæˆ‘ä»¬ç¡®è®¤ SCUBE3 æ˜¯æ”¯æŒç”Ÿå­˜å’Œæ²»ç–—è€è¯æ€§çš„å…³é”®å› ç´ ï¼ŒåŒæ—¶ä¹Ÿè°ƒèŠ‚å…ç–«æŠ‘åˆ¶æ€§è‚¿ç˜¤å¾®ç¯å¢ƒã€‚åˆ†æ³Œæ€§ SCUBE3 é€šè¿‡ä¸å…³é”®è‡´ç™Œç»†èƒè¡¨é¢å—ä½“è›‹ç™½ï¼ˆåŒ…æ‹¬ EGFRã€çªå˜ CALR å’Œ TGFÎ²RI/IIï¼‰çš„ç›¸äº’ä½œç”¨æ”¯æŒè‡´ç™Œæ´»æ€§ã€‚è¿™äº›ç›¸äº’ä½œç”¨æ¿€æ´»äº†è½¬å½•å› å­ FOXR2 å’Œ c-Mycï¼Œé€šè¿‡å¢å¼º DNA æŸä¼¤ä¿®å¤ï¼Œä¿ƒè¿›ç™Œç»†èƒå¢æ®–å’Œæ²»ç–—è€è¯æ€§ã€‚æ­¤å¤–ï¼ŒSCUBE3-FOXR2 è½´é€šè¿‡ä¿ƒè¿› DNMT1 è¡¨è§‚é—ä¼ æŠ‘åˆ¶å¤åˆç‰©æ‹›å‹Ÿè‡³è½¬å½•è°ƒæ§ IRF1ï¼Œä»è€ŒæŠ‘åˆ¶ MHC-I å’Œ MHC-II åŸºå› çš„è¡¨è¾¾ï¼Œåˆ›é€ äº†å…ç–«æŠ‘åˆ¶æ€§è‚¿ç˜¤å¾®ç¯å¢ƒã€‚ä¸€ç§é¦–åˆ›çš„é’ˆå¯¹ SCUBE3 çš„ä¸­å’ŒæŠ—ä½“ï¼Œåˆ©ç”¨å…ˆè¿›çš„æŠ—ä½“å‘ç°å¹³å°å¼€å‘ï¼Œå¹¶é€šè¿‡é‡é“¾ä¸­ç‰¹å®šçªå˜å·¥ç¨‹åŒ–ï¼Œå¢å¼ºç‰¹å¼‚æ€§å’Œç–—æ•ˆï¼Œåœ¨åŒ…æ‹¬ä¹³è…ºç™Œå’Œåµå·¢ç™Œæ‚£è€…<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996335691649363968/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç™Œç—‡ä¸­çš„é“å‡‹äº¡ï¼šä»£è°¢ã€æœºåˆ¶åŠæ²»ç–—å‰æ™¯ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€ä»£è°¢<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: é“å‰¥è½æ˜¯ä¸€ç§ç»†èƒæ­»äº¡çš„å½¢å¼ï¼ŒåŒºåˆ«äºç»†èƒå‡‹äº¡ã€åæ­»å’Œè‡ªå™¬ã€‚è¿™æ˜¯ä¸€ç§æ–°å‹çš„ç¨‹åºæ€§ç»†èƒæ­»äº¡ï¼ˆPCDï¼‰ï¼Œç”±é“çš„ç§¯ç´¯å’Œè¿‡æ°§åŒ–è§¦å‘ï¼Œä¸ç»†èƒå†…é“ä»£è°¢ç–¾ç—…ç›¸å…³ã€‚è‡ª 2012 å¹´å‘½åä»¥æ¥ï¼Œé“å‰¥èš€å› å…¶åœ¨äººç±»ç–¾ç—…ä¸­çš„ä½œç”¨è€Œå—åˆ°è¶Šæ¥è¶Šå¤šçš„å…³æ³¨ï¼Œå°¤å…¶æ˜¯åœ¨è‚¿ç˜¤å½¢æˆã€è¿›å±•å’Œæ²»ç–—æ–¹é¢ã€‚å¤§é‡ç ”ç©¶è¡¨æ˜ï¼Œé“æ¶ˆäº¡åœ¨æ€æ­»è‚¿ç˜¤ç»†èƒã€æŠ‘åˆ¶è‚¿ç˜¤å¢æ®–å’Œè½¬ç§»ä»¥åŠé€†è½¬æ²»ç–—è€è¯æ€§æ–¹é¢èµ·ç€å…³é”®ä½œç”¨ã€‚å› æ­¤ï¼Œé’ˆå¯¹è‚¿ç˜¤ç»†èƒä¸­é“å‰¥è½ç—‡çš„é¶å‘è¯±å¯¼è¢«è§†ä¸ºä¸€ç§æ–°å‹æŠ—è‚¿ç˜¤æ²»ç–—ç­–ç•¥ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996243651410374656/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>æŠ—ä½“æ­£ç”µå­å‘å°„æ–­å±‚æ‰«æåœ¨ç™Œç—‡å½±åƒä¸­çš„ä¸´åºŠè½¬åŒ–ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: è‚ç»†èƒç™Œï¼ˆHCCï¼‰ç¼ºä¹ç²¾ç¡®ä¸”éä¾µå…¥æ€§çš„è¯Šæ–­å·¥å…·ã€‚ä¸ºæ­¤ï¼Œå¼€å‘äº†ä¸€ç§æ–°çš„æ­£ç”µå­å‘å°„æ–­å±‚æ‰«æï¼ˆPETï¼‰æ”¾å°„ç¤ºè¸ªå‰‚[68Ga]Ga-XH-06ã€‚å®ƒåˆ©ç”¨æŠ—ä½“ç‰‡æ®µé¶å‘é«˜åº¦ç‰¹å¼‚æ€§çš„ç”Ÿç‰©æ ‡å¿—ç‰©è‰ç”˜-3ï¼ˆGPC3ï¼‰ï¼ŒæˆåŠŸè§‚å¯Ÿè‚ç»†èƒç™Œæ‚£è€…çš„ GPC3 è¡¨è¾¾ï¼Œå¯èƒ½æ»¡è¶³é‡è¦çš„æœªæ»¡è¶³éœ€æ±‚ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996247001749106688/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>å°†å—æŸçº¿ç²’ä½“ä»ç™Œç»†èƒè½¬ç§»åˆ°ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼Œä¿ƒè¿› EGFR çªå˜è‚ºç™Œä¸­é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚è€å—æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šçº¿ç²’ä½“ã€æ¿€é…¶<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: è€è¯æŒä¹…ä½“ï¼ˆDTPï¼‰ç»†èƒé©±åŠ¨ EGFR çªå˜è‚ºè…ºç™Œçš„æ²»ç–—è€è¯æ€§ã€‚åˆ©ç”¨å•ç»†èƒ RNA æµ‹åºï¼Œæˆ‘ä»¬é‰´å®šå‡ºä¸€ä¸ªä¸´åºŠæ˜¾è‘—çš„ RGS5+MYL9+ç™Œç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFï¼‰ç¾¤ä½“ï¼Œè¯¥ç¾¤ä½“ä¸ EGFR é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚ï¼ˆTKIï¼‰è€è¯æ€§å’Œé¢„åè¾ƒå·®ç›¸å…³ã€‚è¿™äº› CAFs é€šè¿‡ CCL11 ä¿¡å·è¢«æ‹›å‹Ÿåˆ° DTP ç”Ÿæ€ä½ï¼Œå¹¶é€šè¿‡ TKI äº§ç”Ÿçš„çº¿ç²’ä½“æ´»æ€§æ°§ï¼ˆROSï¼‰è¯±å¯¼çš„ Miro1/RhoA æ¿€æ´»å½¢æˆéš§ç©¿çº³ç±³ç®¡ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼ŒRGS5+MYL9+ CAFs é€šè¿‡æ¥å—è‚¿ç˜¤æ¥æºçš„å—æŸçº¿ç²’ä½“ï¼Œä½œä¸ºâ€œä»£è°¢æ±‡â€ï¼Œä»è€Œä¿ƒè¿› DTP å­˜æ´»ã€‚ä½¿ç”¨æ³•è‹åœ°å°”ï¼ˆä¸€ç§ Rho æ¿€é…¶æŠ‘åˆ¶å‰‚ï¼‰æ²»ç–—ï¼Œæœ‰æ•ˆé˜»æ–­çº¿ç²’ä½“è½¬ç§»ï¼Œå¹¶åœ¨ä½“å†…æ¢å¤äº†å¯¹ EGFR-TKI å¥¥è¥¿é»˜æ›¿å°¼çš„æ•æ„Ÿæ€§ã€‚æœ¬ç ”ç©¶å…±åŒæ­ç¤ºäº†å¯é¶å‘çš„åŸºè´¨-è‚¿ç˜¤ä¸²æ‰°ï¼Œè¿™äº›ç›¸äº’ä½œç”¨ç»´æŒ DTP ç¾¤ä½“ï¼Œæå‡ºäº†å…‹æœ EGFR-TKI è€è¯æ€§çš„è”åˆç–—æ³•ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996335645147115520/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>ç™Œç—‡è½¬å½•ç»„è§£å·ç§¯æŒ‡å—ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€è½¬å½•ç»„<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç™Œç»„ç»‡æ˜¯è‚¿ç˜¤ã€åŸºè´¨å’Œå…ç–«ç»†èƒçš„å¼‚è´¨æ··åˆä½“ï¼Œæ¯ä¸ªç»„æˆéƒ¨åˆ†åŒ…å«å¤šç§ä¸åŒçš„ç»†èƒç±»å‹å’Œ/æˆ–çŠ¶æ€ã€‚ç»˜åˆ¶è¿™ç§å¼‚è´¨æ€§å›¾è°±å¹¶ç†è§£æ¯ç§ç»†èƒç±»å‹å¯¹è‚¿ç˜¤è½¬å½•ç»„çš„ç‹¬ç‰¹è´¡çŒ®å¯¹äºæ¨åŠ¨ç™Œç—‡ç”Ÿç‰©å­¦çš„å‘å±•è‡³å…³é‡è¦ï¼Œç„¶è€Œè‚¿ç˜¤ç»„ç»‡çš„é«˜é€šé‡è¡¨è¾¾è°±ä»…ä»£è¡¨æ¥è‡ªæ‰€æœ‰ç»†èƒæ¥æºçš„ç»¼åˆä¿¡å·ã€‚å¯¹è¿™äº›æ··åˆä¿¡å·çš„è®¡ç®—è§£å·ç§¯å·²æˆä¸ºå‰–æç»†èƒç»„æˆå’Œç»†èƒç±»å‹ç‰¹å¼‚è¡¨è¾¾æ¨¡å¼çš„æœ‰åŠ›æ–¹æ³•ã€‚æœ¬æ–‡ä¸ºç™Œç—‡ç ”ç©¶äººå‘˜æä¾›ä¸€ä»½å…¨é¢çš„è½¬å½•ç»„å»å·ç§¯æŒ‡å—ï¼Œä¸“é—¨é’ˆå¯¹ç™Œç—‡ç ”ç©¶äººå‘˜ï¼Œæå‡ºäº†ä¸€ä¸ªç³»ç»Ÿæ¡†æ¶ï¼Œå¸®åŠ©é€‰æ‹©å’Œåº”ç”¨å»å·ç§¯æ–¹æ³•ï¼ŒåŒæ—¶è€ƒè™‘è‚¿ç˜¤ç»„ç»‡çš„ç‹¬ç‰¹å¤æ‚æ€§ã€æ•°æ®å¯ç”¨æ€§å’Œæ–¹æ³•å‡è®¾ã€‚æˆ‘ä»¬è¯¦ç»†ä»‹ç»äº†43ç§è§£å·ç§¯æ–¹æ³•ï¼Œå¹¶æ¦‚è¿°äº†ä¸åŒæ–¹æ³•åœ¨ç™Œç—‡ç ”ç©¶ä¸­å„è‡ªçš„ç‹¬ç‰¹åº”ç”¨ï¼šä»ç†è§£è‚¿ç˜¤å…ç–«ç›‘æµ‹åˆ°è¯†åˆ«ç™Œç—‡äºšå‹ã€å‘ç°é¢„åç”Ÿç‰©æ ‡å¿—ç‰©ä»¥åŠè¡¨å¾ç©ºé—´è‚¿ç˜¤ç»“æ„ã€‚é€šè¿‡åˆ†æè¿™äº›æ–¹æ³•çš„èƒ½åŠ›ä¸å±€é™æ€§ï¼Œæˆ‘ä»¬çªæ˜¾äº†æ–°å…´è¶‹åŠ¿å’Œæœªæ¥æ–¹å‘ï¼Œç‰¹åˆ«æ˜¯åœ¨è‚¿ç˜¤ç»†èƒå¯å¡‘æ€§å’ŒåŠ¨æ€ç»†èƒçŠ¶æ€æ–¹é¢çš„ç ”ç©¶ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996338018154295296/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>2025å¹´ç™Œç—‡ç ”ç©¶è¿›å±•çš„åæ€ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996244811605192704/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GFER æ˜¯èƒ°è…ºè…ºç™Œä¸­æ°§åŒ–è¿˜åŸç¨³æ€ç ´åå’Œå…ç–«ååº”å†æ¿€æ´»çš„é¶ç‚¹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒ°ç®¡è…ºç™Œï¼ˆPDACï¼‰çš„ä»£è°¢å¤±è°ƒå’Œå…ç–«æŠ‘åˆ¶æ€§è‚¿ç˜¤å¾®ç¯å¢ƒå‡å¯¼è‡´è¯¥è‡´å‘½ç–¾ç—…çš„æ²»ç–—è¿Ÿç¼“ã€‚å› æ­¤ï¼Œæˆ‘ä»¬æ—¨åœ¨é‰´å®šå¹¶è¡¨å¾ä¸€ç§é€šè¿‡ç ´åç™Œç»†èƒæ°§åŒ–è¿˜åŸç¨³æ€å’Œæé«˜ PDAC å…ç–«åŸæ€§æ¥å¼•å‘æŠ—ç™Œååº”çš„é¶ç‚¹ã€‚é¦–å…ˆï¼Œé€šè¿‡ä½¿ç”¨å¸¦æœ‰è‡ªå®šä¹‰ sgRNA æ–‡åº“çš„ CRISPR-Cas9 ç­›é€‰ç³»ç»Ÿï¼Œé‰´å®šäº† PDAC ä¸­çš„çº¿ç²’ä½“ä»£è°¢ä¾èµ–æ€§ã€‚åŠŸèƒ½éªŒè¯åˆ†ææ˜¾ç¤º GFER æ˜¯ä¸€ç§çº¿ç²’ä½“ä¾èµ– FAD çš„ç£ºç¢±æ°§åŒ–é…¶ï¼Œæ˜¯è‚¿ç˜¤ç”Ÿé•¿çš„é‡è¦è°ƒæ§å› å­ã€‚ä½“å¤–å’Œä½“å†…æ–¹æ³•å­¦è¡¨æ˜ï¼ŒGFER è€—ç«­æ‰°ä¹±äº†æ°§åŒ–è¿˜åŸç¨³æ€ï¼Œå¹¶åˆºæ¿€è‚¿ç˜¤å…ç–«åŸæ€§ï¼ŒåŒ…æ‹¬å¯¹å…ç–«æ£€æŸ¥ç‚¹é˜»æ–­çš„æ•æ„ŸåŒ–ã€‚åœ¨æ‚£è€…è¡ç”Ÿçš„ PDAC å¼‚ç§ç§»æ¤æ¨¡å‹ä¸­ï¼ŒGFER è€—ç«­è¯±å¯¼çš„ç”Ÿé•¿æŠ‘åˆ¶ååº”æ˜¯ç”±æ”¹å˜çš„æ°§åŒ–å¹³è¡¡ä»‹å¯¼ï¼Œè¯¥ååº”é‡Šæ”¾å—æŸçš„çº¿ç²’ä½“ DNA è¿›å…¥è‚¿ç˜¤ç»†èƒè´¨ï¼Œä»è€Œæ¿€æ´» cGAS-STING é€šè·¯å¹¶è¡¨è¾¾ I å‹å¹²æ‰°ç´ ã€‚è¿™ä¸€æ•ˆåº”åœ¨ä¸€ä¸ªå°é¼ å…ç–«æ­£å¸¸çš„åˆæˆ PDAC æ¨¡å‹ä¸­å¾—ä»¥é‡ç°ï¼Œå…¶ä¸­ GFER è€—ç«­æŠ‘åˆ¶è‚¿ç˜¤ç”Ÿé•¿ï¼Œä¿ƒè¿›<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996335682262511616/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>å¤šç»„å­¦è°±åˆ†æä¸ºå°ç»†èƒè‚ºç™Œçš„å¼‚è´¨æ€§ã€å¾®ç¯å¢ƒç‰¹å¾åŠç”Ÿç‰©æ ‡å¿—ç‰©æ™¯è§‚æä¾›äº†è§è§£ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå¾®ç”Ÿç‰©<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒŒæ™¯ éœ€è¦æ›´æ·±å…¥ç†è§£å°ç»†èƒè‚ºç™Œï¼ˆSCLCï¼‰ä¸­é’ˆå¯¹å…ç–«æ²»ç–—çš„æ²»ç–—æ•æ„Ÿæ€§å·®å¼‚ã€‚æ–¹æ³• æˆ‘ä»¬é€šè¿‡å¯¹ 159 åæœªæ²»ç–—æ‚£è€…çš„è‚¿ç˜¤ç»„ç»‡æ ·æœ¬è¿›è¡Œæ•´åˆåˆ†å­è¡¨å¾ï¼Œåˆ©ç”¨é—ä¼ ã€è¡¨è§‚é—ä¼ ã€è½¬å½•å’Œè›‹ç™½è´¨ç»„åˆ†æï¼Œå¯¹å¤šç§ç”Ÿç‰©å­¦ç›¸å…³æ ‡å¿—ç‰©ï¼ˆåŒ…æ‹¬è½¬å½•äºšå‹å®šä¹‰è›‹ç™½ï¼‰è¿›è¡Œå…ç–«ç»„åŒ–å­¦æŸ“è‰²ï¼Œä»¥åŠå¤šé‡å…ç–«è§å…‰ç©ºé—´å…ç–«åˆ†æï¼Œæ¢ç´¢äº† SCLC çš„å¼‚è´¨æ€§ã€‚ç»“æœ å¤šç»„å­¦åˆ†æè¯å®ç¥ç»å†…åˆ†æ³Œå’Œéç¥ç»å†…åˆ†æ³Œäºšå‹ä¹‹é—´å­˜åœ¨é«˜åº¦å¼‚è´¨æ€§ã€‚ç”²åŸºç»„å­¦åˆ†æç¡®å®šäº†å››ä¸ªç”²åŸºç»„ç°‡ï¼Œå¯èƒ½å¢å¼ºäºšå‹é¢„æµ‹ã€é¢„ååŠäºšå‹æ¼”åŒ–çš„çºµå‘ç›‘æµ‹ã€‚å…ç–«ç»„åŒ–åˆ†ææ˜¾ç¤ºéç¥ç»å†…åˆ†æ³Œäºšå‹ä¸­ MHC-I è¡¨è¾¾è¾ƒé«˜ï¼Œè¿™äº›äºšå‹åœ¨åŒ–ç–—ä¸­åŠ å…¥å…ç–«æ²»ç–—å…·æœ‰æœ€å¤§æ½œåœ¨ç›Šå¤„;ä¸ç¥ç»å†…åˆ†æ³Œäºšå‹åŠå…ç–«æ€§å†·æ€§è‚¿ç˜¤å¾®ç¯å¢ƒç›¸å…³çš„é«˜ DLL3 è¡¨è¾¾ã€‚å¤šé‡å…ç–«è§å…‰æ˜¾ç¤º MHC-I ä¸é«˜ MHC-I è¡¨è¾¾ SCLC è‚¿ç˜¤å¾®ç¯å¢ƒä¸­å…ç–«ç»†èƒçš„ç©ºé—´æ’åˆ—å’Œè¡¨å‹ç‰¹å¾ç›¸å…³ï¼Œä¸º MHC-I ä½œä¸ºå…ç–«æ²»ç–—ååº”æ½œåœ¨ç”Ÿç‰©æ ‡å¿—ç‰©æä¾›äº†æœºåˆ¶ä¾æ®ã€‚ç»“è®º è¿™ä¸€å¤šæ¨¡æ€å‰–æåˆ†æè¿›ä¸€æ­¥æ­ç¤ºäº†<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996337968997052416/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>è€å¹´ç™Œç—‡æ‚£è€…è€å¹´è¯„ä¼°ä¸ç®¡ç†çš„æˆæœ¬æ•ˆç”¨ï¼šä»è¯æ®åˆ°å®æ–½ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1996335846456930304/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 1 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æœŸåˆŠæ–‡ç« ">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>13</td>
</tr>
<tr>
<td>cancer</td>
<td>13</td>
</tr>
<tr>
<td>immune</td>
<td>11</td>
</tr>
<tr>
<td>tumor</td>
<td>10</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>7</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>7</td>
</tr>
<tr>
<td>spatial</td>
<td>6</td>
</tr>
<tr>
<td>transcriptome</td>
<td>6</td>
</tr>
<tr>
<td>resistance</td>
<td>6</td>
</tr>
<tr>
<td>spatial transcriptomics</td>
<td>4</td>
</tr>
<tr>
<td>pathway</td>
<td>4</td>
</tr>
<tr>
<td>single-cell</td>
<td>4</td>
</tr>
<tr>
<td>carcinoma</td>
<td>3</td>
</tr>
<tr>
<td>genome</td>
<td>3</td>
</tr>
<tr>
<td>æŠ—ä½“</td>
<td>3</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>3</td>
</tr>
<tr>
<td>Hi-C</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>2</td>
</tr>
<tr>
<td>sequencing</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (53æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303995" target="_blank" rel="noopener noreferrer">GSE303995 äººç±»èƒ¶è´¨æ¯ç»†èƒç˜¤å’Œè„‘è†œç˜¤ä¸­ç‰¹å¼‚æ€§è‚¿ç˜¤å†…å¾®ç”Ÿç‰©ç»„ç‰¹å¾ï¼šè‚ -è„‘å¾®ç”Ÿç‰©è½´çš„è¯æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271116" target="_blank" rel="noopener noreferrer">GSE271116 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºäº†å¸•é‡‘æ£®ç—…äººç±»ä¸­è„‘æ ·å™¨å®˜æ¨¡å‹ä¸­çš„åˆ†å­è„†å¼±æ€§ [scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271115" target="_blank" rel="noopener noreferrer">GSE271115 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºäº†å¸•é‡‘æ£®ç—…äººç±»ä¸­è„‘æ ·ç±»å™¨å®˜æ¨¡å‹ä¸­çš„åˆ†å­è„†å¼±æ€§ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311908" target="_blank" rel="noopener noreferrer">GSE311908 ä¸€ä¸ªå¯é¶å‘çš„å‘è‚²ç¨‹åºå…±åŒè°ƒæ§è¡€ç®¡ç”Ÿæˆå’Œå…ç–«é€ƒé€¸ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311907" target="_blank" rel="noopener noreferrer">GSE311907 ä¸€ä¸ªå¯é¶å‘çš„å‘è‚²ç¨‹åºå…±åŒè°ƒèŠ‚è¡€ç®¡ç”Ÿæˆå’Œå…ç–«é€ƒé€¸ [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311906" target="_blank" rel="noopener noreferrer">GSE311906 ä¸€ä¸ªå¯é¶å‘çš„å‘è‚²ç¨‹åºå…±åŒè°ƒæ§è¡€ç®¡ç”Ÿæˆå’Œå…ç–«é€ƒé€¸ [ChIP-seqã€ATACseq å’Œ CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287963" target="_blank" rel="noopener noreferrer">GSE287963 ç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒè¡ç”Ÿçš„CCL5ä¿ƒè¿›ç¥ç»å†…åˆ†æ³Œå‰åˆ—è…ºç™Œçš„é¡ºé“‚è€è¯æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283755" target="_blank" rel="noopener noreferrer">GSE283755 è¯ç‰©æ²»ç–—å¯¹å­å®«å†…è†œå¼‚ä½ç—‡æ‚£è€…æ¶æ€§è½¬åŒ–ä¸ºé€æ˜ç»†èƒç™Œçš„å½±å“ï¼šåŸºäºä¸‹ä¸€ä»£æµ‹åºï¼ˆNGSï¼‰çš„åŸºå› è¡¨è¾¾æ¯”è¾ƒç ”ç©¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310353" target="_blank" rel="noopener noreferrer">GSE310353 èƒ°è…ºç™ŒåŸä½å¤šæ¨¡æ€è¡¨å¾æ­ç¤ºè‚¿ç˜¤ç»†èƒç‰¹æ€§æ˜¯å‘¨å›´å¾®ç¯å¢ƒçš„å†³å®šæ€§å› ç´ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310352" target="_blank" rel="noopener noreferrer">GSE310352 èƒ°è…ºç™ŒåŸä½å¤šæ¨¡æ€è¡¨å¾æ­ç¤ºè‚¿ç˜¤ç»†èƒç‰¹æ€§æ˜¯å‘¨å›´å¾®ç¯å¢ƒçš„å†³å®šæ€§å› ç´  [Nanostring CosMx]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307850" target="_blank" rel="noopener noreferrer">GSE307850 å·¨å™¬ç»†èƒè°ƒèŠ‚ILC2ä¸ŠPD-1å’ŒCTLA-4çš„è¡¨è¾¾åŠå…¶åœ¨è‚¿ç˜¤å¾®ç¯å¢ƒä¸­çš„ååº”æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281045" target="_blank" rel="noopener noreferrer">GSE281045 Ctcf f/f å’Œ Ctcf Î”/Î” CALM-AF10 AML ç»†èƒä¸­ H3K4kme3ã€H3K27ac å’Œ H3K27me3 çš„å…¨åŸºå› ç»„å®šä½ [Tgm2 RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281044" target="_blank" rel="noopener noreferrer">GSE281044 Ctcf f/f å’Œ Ctcf Î”/Î” CALM-AF10 AML ç»†èƒä¸­ H3K4kme3ã€H3K27ac å’Œ H3K27me3 çš„å…¨åŸºå› ç»„å®šä½ [CTCF RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281043" target="_blank" rel="noopener noreferrer">GSE281043 Ctcf f/f å’Œ Ctcf Î”/Î” CALM-AF10 AML ç»†èƒä¸­ H3K4kme3ã€H3K27ac å’Œ H3K27me3 çš„å…¨åŸºå› ç»„å®šä½ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305400" target="_blank" rel="noopener noreferrer">GSE305400 ç ”ç©¶å‘ç°ï¼ŒSTING è¯±å¯¼çš„è¡€è„‘å±éšœå¼€æ”¾ä¸æ”¾å°„ç–—æ³•è”åˆåº”ç”¨å¯å¢å¼ºæŠ—èƒ¶è´¨ç˜¤å…ç–«å’Œæ²»ç–—æ´»æ€§ï¼Œè¯¥æ´»æ€§å¯é€šè¿‡ [18F]-FLT PET ç›‘æµ‹ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311895" target="_blank" rel="noopener noreferrer">GSE311895 çº¿ç²’ä½“ç¡¬åº¦ç›¸å…³è½¬ç§»é€šè¿‡ä»£è°¢é‡ç¼–ç¨‹ä¿ƒè¿›è‚¿ç˜¤è¿›å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271118" target="_blank" rel="noopener noreferrer">GSE271118 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºäº†å¸•é‡‘æ£®ç—…äººç±»ä¸­è„‘æ ·å™¨å®˜æ¨¡å‹ä¸­çš„åˆ†å­è„†å¼±æ€§ [MERFISH]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE183843" target="_blank" rel="noopener noreferrer">GSE183843 FBXO11 çš„ç¼ºå¤±é€šè¿‡ LONP1 å¤±è°ƒåœ¨æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­å»ºç«‹å¹²ç»†èƒç¨‹åº [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312352" target="_blank" rel="noopener noreferrer">GSE312352 IL-22 è¯±å¯¼æºƒç–¡æ€§ç»“è‚ ç‚ç»“è‚ ä¸Šçš®ç»†èƒå‘ç”Ÿæ½˜æ°ç»†èƒåŒ–ç”Ÿï¼Œé€šè¿‡ REG3A ä¿ƒè¿›ä¼¤å£æ„ˆåˆ [å°é¼  RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312136" target="_blank" rel="noopener noreferrer">GSE312136 é«˜åˆ†è¾¨ç‡ä½“å†…ç»“åˆæ•°æ®æ˜¾ç¤ºï¼ŒTBP åœ¨æœ‰æˆ–æ²¡æœ‰ TFIID çš„æƒ…å†µä¸‹å‡å¯åœ¨ TATA å¯åŠ¨å­å¤„å¯åŠ¨è½¬å½• [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311910" target="_blank" rel="noopener noreferrer">GSE311910 ä¸€ä¸ªå¯é¶å‘çš„å‘è‚²ç¨‹åºå…±åŒè°ƒæ§è¡€ç®¡ç”Ÿæˆå’Œå…ç–«é€ƒé€¸ [scRNAseq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307724" target="_blank" rel="noopener noreferrer">GSE307724 è‚¥å¤§ç»†èƒç±»èƒ°è›‹ç™½é…¶è¯±å¯¼ä¹³è…ºç™Œç»†èƒæ ¸é‡å¡‘å¹¶æŠ‘åˆ¶å…¶ç”Ÿé•¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306834" target="_blank" rel="noopener noreferrer">GSE306834 EC359 é€šè¿‡æŠ‘åˆ¶ LIFR ä¿¡å·é€šè·¯å¢å¼ºæ›²ç¾æ›¿å°¼åœ¨ Ras/Raf é©±åŠ¨çš„åµå·¢ç™Œä¸­çš„ç–—æ•ˆ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE306270" target="_blank" rel="noopener noreferrer">GSE306270 ä½æ°®èƒè¿«ä¸‹ä¹Œè‹é‡Œæ¨è½¬å½•ç»„å“åº”åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305912" target="_blank" rel="noopener noreferrer">GSE305912 ç»’æ¯›è›‹ç™½æ ·è›‹ç™½é€šè¿‡ä¸‹è°ƒMYCæŠ‘åˆ¶é¼»å’½ç™Œå¢æ®–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299157" target="_blank" rel="noopener noreferrer">GSE299157 D419Nçªå˜å¯¹EuMycå°é¼ æ·‹å·´ç˜¤ç»†èƒä¸­STAT6è½¬å½•å› å­æ´»æ€§çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295068" target="_blank" rel="noopener noreferrer">GSE295068 è’½ç¯ç±»è¯ç‰©é€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§ALDH1çš„è¡¨è¾¾ï¼Œå¯¼è‡´æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰äº§ç”Ÿé€‚åº”æ€§æ°§åŒ–ååº”å’Œè€è¯æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290907" target="_blank" rel="noopener noreferrer">GSE290907 ZDHHC12 æ£•æ¦ˆé…°åŒ– HDAC8 å¹¶ä¿ƒè¿›ä¸é«˜é¥±å’Œè„‚è‚ªé…¸é¥®é£Ÿç›¸å…³çš„è‚ç»†èƒç™Œçš„å‘ç”Ÿå‘å±•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE227658" target="_blank" rel="noopener noreferrer">GSE227658 åˆ©ç”¨è½¬å½•ç»„æ–­å±‚æ‰«ææŠ€æœ¯å¯¹äº¨å»·é¡¿ç—…æ¨¡å‹å°é¼  R6/2 å‡ºç”Ÿå 5 å‘¨çš„æ­£å¸¸åŒçªå¯¹ç…§å°é¼ å…¨è„‘è¿›è¡ŒåŸºå› è¡¨è¾¾è°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE227657" target="_blank" rel="noopener noreferrer">GSE227657 åˆ©ç”¨è½¬å½•ç»„æ–­å±‚æ‰«ææŠ€æœ¯å¯¹äº¨å»·é¡¿ç—…æ¨¡å‹å°é¼  R6/2 å‡ºç”Ÿå 5 å‘¨çš„å…¨è„‘è¿›è¡ŒåŸºå› è¡¨è¾¾è°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312051" target="_blank" rel="noopener noreferrer">GSE312051 ç§€ä¸½éšæ†çº¿è™«è½¬å½•ç»„å’Œè¡¨å‹ä¸Šä½æ€§åˆ†ææ­ç¤ºäº† daf-2/InsR åœ¨ L1 æœŸé˜»æ»å’Œæ¢å¤è¿‡ç¨‹ä¸­ daf-16/FoxO ä¾èµ–æ€§å’Œéä¾èµ–æ€§æ•ˆåº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311502" target="_blank" rel="noopener noreferrer">GSE311502 3â€™UTRè¡ç”Ÿçš„å°RNAè°ƒèŠ‚éœä¹±æ¯’ç´ ç¼–ç ä¸çŠ¶å™¬èŒä½“CTXÏ•çš„ç”Ÿå‘½å‘¨æœŸ[RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303819" target="_blank" rel="noopener noreferrer">GSE303819 æ¯ä½“è¡€æ¶²è½¬å½•ç»„åæ˜ äº†èƒå„¿ç”Ÿé•¿å˜åŒ–ï¼Œå¹¶ä¸”æ˜¯ç‰›å‡ºç”Ÿä½“é‡çš„å‡†ç¡®é¢„æµ‹æŒ‡æ ‡ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298445" target="_blank" rel="noopener noreferrer">GSE298445 SOX10 é€šè¿‡ IRF1-ITGA3/EphA2-FAK é€šè·¯è°ƒæ§é»‘è‰²ç´ ç˜¤è½¬ç§»ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295359" target="_blank" rel="noopener noreferrer">GSE295359 å¤§è§„æ¨¡å•ç»†èƒåˆ†ææ­ç¤ºäº†ä¸åŒç§å¼‚ä½“é€ è¡€å¹²ç»†èƒç§»æ¤åæ€¥æ€§ç§»æ¤ç‰©æŠ—å®¿ä¸»ç—…ç›¸å…³çš„æ–°å‹ç”Ÿç‰©æ ‡å¿—ç‰©</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294627" target="_blank" rel="noopener noreferrer">GSE294627 åˆ©ç”¨äººç±»å¤šèƒ½å¹²ç»†èƒè¡ç”Ÿçš„å¿ƒè‚Œç»†èƒå’Œ3Då¿ƒè„å¾®ç»„ç»‡æ¨¡æ‹Ÿå¿ƒè‚Œç”Ÿç†ç”Ÿé•¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287043" target="_blank" rel="noopener noreferrer">GSE287043 ç»“èŠ‚ç—…ä¸­ç‹¬ç‰¹çš„ç»“æ ¸åˆ†ææ†èŒç‰¹å¼‚æ€§è¡€æ¶²å…ç–«ç‰¹å¾ï¼šå¯¹ä¸´åºŠè¯Šæ–­çš„æ„ä¹‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279320" target="_blank" rel="noopener noreferrer">GSE279320 å£æœè‘¡èšç³–ç¡«é…¸é’ æ²»ç–—åï¼Œé‡ç”Ÿå‹å’Œ VISTA-KO å°é¼ ç»“è‚  CD45+ ç»†èƒçš„å•ç»†èƒ RNA æµ‹åºæ•°æ®ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278119" target="_blank" rel="noopener noreferrer">GSE278119 ç ”ç©¶å‘ç°ï¼Œå…‹éš†æ‰©å¢çš„æ•ˆåº” CD4+ ç»†èƒæ¯’æ€§ T æ·‹å·´ç»†èƒä¸å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚æ²»ç–—åä¸¥é‡çš„ç¥ç»ç³»ç»Ÿä¸è‰¯äº‹ä»¶ç›¸å…³ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271486" target="_blank" rel="noopener noreferrer">GSE271486 æ„å»ºå¯è½¬ç§»çš„NGSç®—æ³•æ¨¡å‹ä»¥é¢„æµ‹EBVç›¸å…³é¼»å’½ç™Œå’Œé«˜å±çªå˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291676" target="_blank" rel="noopener noreferrer">GSE291676 TSnifferï¼šRNA ç¼–è¾‘ä½ç‚¹çš„æ— åä»å¤´è¯†åˆ«å’Œ RNA-seq æ•°æ®ä¸­ç¼–è¾‘æ´»æ€§çš„å®šé‡åˆ†æ [é‡æ–°åˆ†æ]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291675" target="_blank" rel="noopener noreferrer">GSE291675 TSnifferï¼šå¯¹ RNA ç¼–è¾‘ä½ç‚¹è¿›è¡Œæ— åå€šçš„ä»å¤´è¯†åˆ«ï¼Œå¹¶é‡åŒ– RNA-seq æ•°æ®ä¸­çš„ç¼–è¾‘æ´»æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312368" target="_blank" rel="noopener noreferrer">GSE312368 ä¸€ä¸ªå¯é¶å‘çš„å‘è‚²ç¨‹åºå…±åŒè°ƒèŠ‚è¡€ç®¡ç”Ÿæˆå’Œå…ç–«é€ƒé€¸ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312339" target="_blank" rel="noopener noreferrer">GSE312339 è±šé¼ èƒå„¿å’Œæ¯ä½“è‚è„è½¬å½•ç»„çš„æ¯”è¾ƒ RNA-seq åˆ†ææ­ç¤ºäº†å¹¿æ³›çš„è½¬å½•å·®å¼‚ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312031" target="_blank" rel="noopener noreferrer">GSE312031 æŸ“è‰²è´¨æ‹“æ‰‘ç»“æ„å’Œ H3K27me3 é‡åˆ†å¸ƒçš„æ—¶ç©ºé‡å¡‘æ˜¯ Hutchinson-Gilford æ—©è¡°ç—‡è¡€ç®¡ç—…ç†çš„åŸºç¡€ [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311894" target="_blank" rel="noopener noreferrer">GSE311894 ç¡’ä»‹å¯¼çš„RUNX2è¿‡è¡¨è¾¾åŠå…¶è½¬å½•ç»„æ”¹å˜å¯¹å¡æ¬£è´å…‹ç—…è½¯éª¨ç»†èƒæŸä¼¤çš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311574" target="_blank" rel="noopener noreferrer">GSE311574 èƒ°è…ºç™Œä¸Šçš®é—´è´¨ç»†èƒå¯å¡‘æ€§çš„æ²»ç–—é¶å‘æ²»ç–—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302100" target="_blank" rel="noopener noreferrer">GSE302100 å°¿å˜§å•¶-DNAç³–è‹·é…¶ç¼ºä¹ä¸è‚¿ç˜¤ç»†èƒå†…åœ¨ç‚ç—‡ä¿¡å·ä¼ å¯¼å—æŠ‘åˆ¶å’Œå¯¹å¤–æºæ€§å¹²æ‰°ç´ çš„æ•æ„Ÿæ€§æ”¹å˜æœ‰å…³</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292740" target="_blank" rel="noopener noreferrer">GSE292740 CPXM2 æ’åˆ—çš„èƒ¶åŸè›‹ç™½å¯¹ PaTu 8988t ç»†èƒåŸºå› è¡¨è¾¾å’Œç»†èƒå†…ä¿¡å·é€šè·¯çš„å½±å“ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292738" target="_blank" rel="noopener noreferrer">GSE292738 ä¸´åºŠè‚¿ç˜¤æ—ç»„ç»‡å’Œèƒ°è…ºå¯¼ç®¡è…ºç™Œæ ·æœ¬ä¸­ä¸åŒçš„åŸºå› è¡¨è¾¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290161" target="_blank" rel="noopener noreferrer">GSE290161 åˆ©ç”¨ CITE-seq å¯¹æµæ„Ÿç›¸å…³è‚ºæ›²éœ‰ç—…è‚ºéƒ¨è¿›è¡Œå…ç–«è°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287134" target="_blank" rel="noopener noreferrer">GSE287134 è›‹æ°¨é…¸é™åˆ¶é€šè¿‡è¡¨è§‚é—ä¼ æŠ‘åˆ¶TGF-Î²/Smad3/Hoxc8/P-TEFbè½´ç¼“è§£è‚¾çº¤ç»´åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283201" target="_blank" rel="noopener noreferrer">GSE283201 å¯¹å¹´è½»ï¼ˆ3 ä¸ªæœˆå¤§ï¼‰å’Œå¹´è€ï¼ˆ22 ä¸ªæœˆå¤§ï¼‰é‡ç”Ÿå‹å°é¼ åœ¨å¯¹ç…§å’Œä¹™é†‡å–‚å…»æ¡ä»¶ä¸‹çš„æµ·é©¬å’Œè‚è„ RNA-seq æ•°æ®è¿›è¡Œæ¯”è¾ƒåŸºå› è¡¨è¾¾è°±åˆ†æã€‚</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æœŸåˆŠæ–‡ç« "></a>ğŸ”¬ æœŸåˆŠæ–‡ç«  å…¶ä»–å†…å®¹ (1æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://m.x-mol.com/paper/1996335853511749632/t" target="_blank" rel="noopener noreferrer">FLIPI24ï¼šæ–°è¯Šæ–­æ»¤æ³¡æ€§æ·‹å·´ç˜¤çš„ç°ä»£é¢„åæ¨¡å‹å’Œä¸´åºŠè¯•éªŒä¸°å¯Œå·¥å…·ã€‚</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-04 21:38</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>